3,4-dihydroxyphenylacetaldehyde has been researched along with 4-hydroxy-2-nonenal in 6 studies
| Studies (3,4-dihydroxyphenylacetaldehyde) | Trials (3,4-dihydroxyphenylacetaldehyde) | Recent Studies (post-2010) (3,4-dihydroxyphenylacetaldehyde) | Studies (4-hydroxy-2-nonenal) | Trials (4-hydroxy-2-nonenal) | Recent Studies (post-2010) (4-hydroxy-2-nonenal) |
|---|---|---|---|---|---|
| 99 | 0 | 50 | 3,034 | 26 | 1,103 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, DG; Brogden, NK; Doorn, JA; Florang, VR; Hurley, TD; Rees, JN | 1 |
| Anderson, DG; Doorn, JA; Florang, VR; Rees, JN | 1 |
| Anderson, DG; Doorn, JA; Florang, VR; Jinsmaa, Y; Rees, JN; Strack, S | 1 |
| Casida, JE; Cooney, A; Ford, B; Goldstein, DS; Jinsmaa, Y; Sullivan, P | 1 |
| Bubacco, L; Plotegher, N | 1 |
| Anderson, EJ; Builta, ZJ; Doorn, JA; Monroe, TB; Nelson, MM | 1 |
1 review(s) available for 3,4-dihydroxyphenylacetaldehyde and 4-hydroxy-2-nonenal
| Article | Year |
|---|---|
Lysines, Achilles' heel in alpha-synuclein conversion to a deadly neuronal endotoxin.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; alpha-Synuclein; Brain; Dopamine; Humans; Lysine; Metabolism; Neurodegenerative Diseases; Neurons | 2016 |
5 other study(ies) available for 3,4-dihydroxyphenylacetaldehyde and 4-hydroxy-2-nonenal
| Article | Year |
|---|---|
Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Aldehyde Reductase; Aldehydes; Animals; Chromatography, High Pressure Liquid; Dopamine; Half-Life; Humans; Mitochondria; Oxidation-Reduction; Oxidative Stress; Rats; Rats, Sprague-Dawley | 2007 |
Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; Animals; Corpus Striatum; Cross-Linking Reagents; Dopamine; Dose-Response Relationship, Drug; Drug Antagonism; Enzyme Inhibitors; Lipid Peroxidation; Malondialdehyde; Oxidative Stress; Rats; Rats, Sprague-Dawley; Synaptosomes | 2007 |
Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Reductase; Aldehydes; Animals; Dopamine; Lipid Peroxidation; Malondialdehyde; Oxidation-Reduction; Oxidative Stress; PC12 Cells; Phenylethyl Alcohol; Rats | 2009 |
Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Aldehydes; Animals; Antifungal Agents; Benomyl; Cell Line; Enzyme Inhibitors; Humans; Lipid Peroxidation; Mice; Parkinson Disease; PC12 Cells; Rats | 2014 |
Biochemical characterization of the catecholaldehyde reactivity of L-carnosine and its therapeutic potential in human myocardium.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aldehydes; Carnosine; Catechols; Cysteine; Glutathione; Humans; Middle Aged; Mitochondria; Myocardium; Oxidation-Reduction | 2019 |